Table 4 Pathological features of both groups
From: Intra-mammary lymph nodes, an overlooked breast cancer prognostic tool?
Variables | Benign IMLNs (N = 42) | Malignant IMLNs (N = 48) | P-value |
|---|---|---|---|
Type of breast surgery | |||
Breast conservative surgery | 6 (14.3%) | 6 (12.5%) | 1C |
Mastectomy | 36 (85.7%) | 42 (87.5%) | |
Type of axillary surgery | |||
SLNB | 6 (14.2%) | 3 (6.25%) | |
Axillary clearance | 36 (85.7%) | 44 (91.6%) | 0.29C |
No surgery | 0 | 1 (2%) | |
Tumor pathology, no. (%) | |||
Invasive duct carcinoma | 37 (88.1%) | 45 (93.7%) | |
Invasive lobular carcinoma | 4 (9.5%) | 3 (6.2%) | 0.56C |
Mucinous carcinoma | 1 (2.3%) | 0 (0%) | |
Hormone receptor status | |||
Luminal A | 18 (42.8%) | 24 (50%) | |
Luminal B | 5 (11.9%) | 7 (14.5%) | 0.45C |
Luminal Her2 | 5 (11.9%) | 9 (18.7%) | |
Her 2 enriched | 8 (19%) | 5 (10.4%) | |
Triple-negative breast cancer | 6 (14.2%) | 3 (6.2%) | |
Associated DCIS, no. (%) | 14 (33.3%) | 20 (41.7%) | 0.43C |
Pathological tumor size (cm) | |||
Mean ± SD | 3.3 ± 1.2 | 4.7 ± 2.6 | 0.001B |
No. of IMLNs | |||
Mean ± SD | 1.2 ± 0.61 | 1.4 ± 0.84 | 0.377B |
Pathological IMLN size | |||
Mean ± SD | 1.1 ± 0.2 | 1.7 ± 0.6 | 0.001B |
Lympho-vascular invasion, no. (%) | |||
Yes | 6 (14.3%) | 31 (65.9%) | 0.001C |
No | 36(85.7%) | 16 (34%) | |
IMLN site pathologically, no. (%) (specified) | |||
Central | 0 | 2 (4.2%) | |
LIQ | 1 (2.4%) | 1 (2.1%) | |
LOQ | 1 (2.4%) | 4 (8.3%) | 0.48C |
UIQ | 6 (14.3%) | 7 (14.6%) | |
UOQ | 32 (76.2%) | 33 (68.8%) | |
UOQ UIQ LOQ | 1 (2.4%) | 0 | |
UOQ LOQ | 1 (2.4%) | 0 | |
UOQ UIQ | 0 | 1 (2.1%) | |
IMLN site pathologically, no. (%) (collected) | |||
UOQ | 34 | 34 | |
Non-UOQ | 8 | 14 | 0.265C |
Extracapsular extension AxLNs, no. (%) | |||
Yes | 7 (16.7%) | 27 (57.4%) | 0.001C |
No | 35 (83.3%) | 21 (44.6%) | |
Pathological T stage | |||
T1 | 2 (4.8%) | 3 (6.3%) | |
T2 | 34 (81%) | 22 (45.8%) | 0.006C |
T3 | 4 (9.5%) | 13 (27.1%) | |
T4 | 2 (4.8%) | 10 (20.8%) | |
Pathological N stage for axilla only | |||
Nx | 0 | 1 | |
N0 | 22 (52.4%) | 13 (27.6%) | 0.002C |
N1 1–3 | 13 (31%) | 9 (19.1%) | |
N2 4–9 | 7 (16.7%) | 14 (29.7%) | |
N3 ≥ 10 | 0 | 11 (23.4%) | |
Pathological N stage including IMLN | |||
Nx | 0 | 1 | |
N0 | 22 (52.4%) | 0 | 0.002C |
N1 1–3 | 13 (31%) | 22 (46.8%) | |
N2 4–9 | 7 (16.7%) | 14 (29.7%) | |
N3 ≥ 10 | 0 | 11 (23.4%) | |